IL-ADTALEM
17.8.2020 08:02:09 CEST | Business Wire | Press release
ACAMS, in partnership with artificial intelligence (AI) company ElephantThink, has successfully conceptualized and delivered its first fully online web-based compliance training program for Dutch banking group ING. The training partnership is for a multi-lingual SaaS solution offering mobile and web-based access to equip recipients with core competencies required to perform analysis, onboarding and anti-money laundering prevention roles and considered pioneering in the world of financial crime prevention training.
ING, which has a presence in over 40 countries serving over 38 million customers, places great emphasis on compliance, know your customer (KYC) / customer due diligence (CDD) and enhanced due diligence (EDD), which is reflected in the 4-year training agreement with ACAMS and ElephantThink.
Under the terms of the partnership, training is delivered digitally via e-learning on the ElephantThink Smart Learning Platform, and accessible in nine languages - English, Dutch, French, German, Italian, Romanian, Spanish, Turkish and Polish. Learners will have the ability to access the web-based learning curriculum supported by a companion mobile application which includes gamification elements to drive engagement and information retention. Qualifying ING employees will receive a verifiable digital certificate upon completion of their training.
Commenting on the training partnership, Roel Louwhoff, chief operations officer and chief transformation officer of ING, said: “As a gatekeeper to the financial system, ING has a responsibility to protect it, our customers and society against financial and economic crimes. Partnering with ACAMS to introduce their internationally recognized and certified digital training enables us to further enhance the KYC knowledge, skills and expertise of our employees in an innovative and engaging manner. This helps to fight financial economic crime, ensuring our customers can continue banking safely and securely as we empower them to stay a step ahead in life and in business.’’
Angela Salter, Interim President of ACAMS, said, “This is our first foray into delivering global web-based training to the KYC / CDD and transaction monitoring (TM) teams, and the promise of accelerated reach and efficacy is especially significant in the current environment. The commitment of ING to support a revolutionary training approach for a highly regulated and constantly evolving operating landscape cemented the success of our ground-breaking partnership with ElephantThink.”
Jack Smies, CEO of ElephantThink, said, “The mix of very high quality content from our partner ACAMS combined with our capabilities on AI, gamification and digital claims can really turbo charge people’s learning, which is reflected in the initial response and results of the training.”
Under the terms of the partnership ACAMS will make available AML, Sanctions, KYC and Transaction Monitoring programmes as well as ACAMS Certified Know Your Customer Associate (CKYCA) training at foundational and intermediate levels. These trainings are available in English, Dutch and multiple other languages, providing front-line and operations teams with the tools to perform KYC, CDD and EDD duties. ING’s sanctions, AML compliance and audit team learners will also have access to the full suite of ACAMS courses for the 2nd and 3rd lines of defence, underpinned by ACAMS’ comprehensive continuous education and alerts programme.
In a separate development, ACAMS has been granted approval by the Netherlands training registry body CRKBO to provide anti-financial crime training on a VAT free basis in the country, representing a savings of 21% on every ACAMS training course procured direct from ACAMS including its gold-standard CAMSTM Certified AML Specialist and recently launched Certified Global Sanctions Specialist (CGSS) qualifications.
About ACAMS®
ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a leading workforce solutions provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime prevention professionals from a wide range of industries. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Its new Certified Global Sanctions Specialist (CGSS) certification commenced in January 2020. Visit acams.org for more information.
About Adtalem Global Education
The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal ) and LinkedIn .
About ElephantThink:
ElephantThink is an Artificial Intelligence company that focuses on algorithms and models. By applying this specifically to employee training and development they created a Smart Learning Platform. This smart learning platform can provide hyper personalization so that the learning is optimized for maximum efficiency per individual learner and is unique in that it adapts to the specific way each participant learns. By using spaced repetition of learning elements that are memory dependent, gamification to ensure user engagement and verifiable certificates and badges for user motivation and recognition ET is able to significantly improve the learner’s development. Visit elephantthink.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
